𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CTLA-4 engagement regulates NF-κB activation in vivo

✍ Scribed by Helena Harlin; Kwang Woo Hwang; David A. Palucki; Oliver Kim; Craig B. Thompson; Mark Boothby; Maria-Luisa Alegre

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
321 KB
Volume
32
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CTLA4 ligation attenuates AP-1, NFAT and
CTLA4 ligation attenuates AP-1, NFAT and NF-κB activity in activated T cells
✍ J. Henry Fraser; Mercedes Rincón; Kathy D. McCoy; Graham Le Gros 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

CTLA4 is currently viewed as a late-appearing T cell surface receptor which is able to inhibit the proliferation of activated T cells. We sought to identify how CTLA4 ligation exerts these anti-proliferative effects by studying its influence on the activities of the relevant nuclear transcription fa

Transcription factor NF-κB activation af
Transcription factor NF-κB activation after in vivo perforant path LTP in mouse hippocampus
✍ Ramiro Freudenthal; Arturo Romano; Aryeh Routtenberg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 552 KB

## Abstract There is increasing evidence that transcription factors (TFs) play a critical role in maintaining later phases of hippocampal long‐term potentiation (LTP). We have been led to study the role in synaptic plasticity of the powerful, yet generally unheralded, NF‐κB TF because it may serve

NF-κB synergizes with NF-AT and NF-IL6 i
NF-κB synergizes with NF-AT and NF-IL6 in activation of the IL-4 gene in T cells
✍ Min Li-Weber; Marco Giaisi; Sven Baumann; Katalin Pálfi; Peter H. Krammer 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 1 views

## Abstract IL‐4 plays a pivotal role in the development of the Th2 cell mediated humoral immune response and causes IgE‐dependent allergic inflammatory diseases. Expression of IL‐4 in differentiated Th2 cells is regulated by transcription factors such as NF‐AT, AP‐1 and NF‐IL6. Recently, increasin

A novel NF-κB inhibitor DHMEQ selectivel
A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo
✍ Mariko Watanabe; Md. Zahidunnabi Dewan; Takamitu Okamura; Masataka Sasaki; Kinji 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 453 KB

Multiple myeloma (MM) is a fatal lymphoid malignancy that is incurable with conventional modalities of chemotherapy. Strong and constitutive activation of nuclear factor kappa B (NF-kappaB) is a common characteristic of MM cells. In our study we successfully target NF-kappaB with a novel NF-kappaB i